Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
Vertex Pharmaceuticals executive Joy Liu, EVP and Chief Legal Officer, sold 978 shares of Common Stock in an open-market transaction on April 1, 2026, at an average price of $449.17 per share. The sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 25, 2025.
Following this planned sale, Liu directly holds 21,833 Vertex shares. The filing characterizes this as a routine insider transaction executed pursuant to a pre-arranged trading plan rather than a discretionary trade based on short-term market views.
Vertex Pharmaceuticals asks shareholders to elect eleven directors, ratify its auditor, approve 2025 executive pay on an advisory basis, adopt a 2026 Stock and Option Plan, and vote on a shareholder written-consent proposal. The meeting will be held virtually on May 13, 2026.
Management highlights 2025 total revenues of $12 billion, 9% growth versus 2024, driven by cystic fibrosis medicines, CASGEVY and the first year of JOURNAVX sales, and reports $12.3 billion in cash and investments at year-end. The proxy emphasizes a broad late-stage pipeline, strong say‑on‑pay support of about 92% in 2025, and a pay‑for‑performance program with a high mix of performance stock units for senior executives.
Vertex Pharmaceuticals (VRTX) Rule 144 notice reporting planned resale of 978 shares of common stock related to a Restricted Stock Vesting event dated 02/17/2025. The filing also lists recent sales by Joy Liu: 1,385 shares on 01/05/2026 for $621,629.55, 812 shares on 02/12/2026 for $375,282.04, 9,320 shares on 02/13/2026 for $4,557,480.00, and 892 shares on 03/02/2026 for $442,396.32.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. On March 27, 2026, she sold 2,329 shares of Common Stock at an average price of $450.95 per share. After this transaction, she directly holds 33,076 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan that Dr. Bozic entered into on November 20, 2025, indicating the timing was set in advance.
Vertex Pharmaceuticals has completed submission of a rolling Biologics License Application to the FDA for povetacicept, seeking potential accelerated approval to treat immunoglobulin A nephropathy in adults. Vertex used a priority review voucher and therefore expects the FDA’s review to be expedited to six months from acceptance versus the typical ten-month review.
Vertex Pharmaceuticals Inc filing shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% following an internal realignment.
The amendment states certain Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538 and that The Vanguard Group, Inc. "no longer has, or is deemed to have, beneficial ownership" of securities held by those subsidiaries. The filing is signed by Ashley Grim on 03/27/2026.
Carmen R. Bozic reported sales of Common stock via Form 144. The filing lists sales dated 02/27/2026 and 03/13/2026 tied to the instrument identifier 2329. The excerpt also shows Restricted Stock Vesting entries dated 02/24/2025 (1687) and 02/26/2025 (642) labeled as compensation.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. On March 13, 2026, Dr. Bozic sold 2,329 shares of Vertex common stock at a price of $481.79 per share, as part of routine portfolio activity.
After this transaction, Dr. Bozic directly held 35,405 shares of Vertex common stock, indicating she retains a substantial ownership stake. The sale was carried out under a pre-established Rule 10b5-1 trading plan, meaning it was scheduled in advance under company-approved guidelines rather than timed opportunistically.
Vertex Pharmaceuticals executive Duncan McKechnie sold 2,633 shares of common stock in an open-market transaction. The sale occurred on March 11, 2026, at an average price of $498.42 per share. After the sale, he directly held 12,489 Vertex shares.
The transaction was made under a company-approved Rule 10b5-1 trading plan that Mr. McKechnie entered into on November 25, 2025, indicating the sale was pre-scheduled rather than opportunistic.